c-Kit

信号通路图

研究领域

抑制剂选择性比较
溶解性比较

目录号	产品目录	溶解度(25°C)
目录号	产品目录	水	DMSO	酒精
S1021	Dasatinib	<1 mg/mL	98 mg/mL	<1 mg/mL
S1026	Imatinib Mesylate (STI571)	118 mg/mL	118 mg/mL	<1 mg/mL
S1042	Sunitinib Malate	<1 mg/mL	15 mg/mL	<1 mg/mL
S1005	Axitinib	<1 mg/mL	35 mg/mL	<1 mg/mL
S1035	Pazopanib HCl (GW786034 HCl)	<1 mg/mL	17 mg/mL	<1 mg/mL
S8757	Ripretinib (DCC-2618)	<1 mg/mL	100 mg/mL	<1 mg/mL
S8721	PDGFR inhibitor 1	<1 mg/mL	97 mg/mL	9 mg/mL
S5077	Regorafenib Monohydrate	-1 mg/mL	100 mg/mL	-1 mg/mL
S1018	Dovitinib (TKI-258, CHIR-258)	<1 mg/mL	30 mg/mL	<1 mg/mL
S1064	Masitinib (AB1010)	<1 mg/mL	100 mg/mL	4 mg/mL
S1207	Tivozanib (AV-951)	<1 mg/mL	20 mg/mL	<1 mg/mL
S1032	Motesanib Diphosphate (AMG-706)	19 mg/mL	100 mg/mL	<1 mg/mL
S1244	Amuvatinib (MP-470)	<1 mg/mL	32 mg/mL	<1 mg/mL
S1220	OSI-930	<1 mg/mL	89 mg/mL	3 mg/mL
S1363	Ki8751	<1 mg/mL	47 mg/mL	<1 mg/mL
S2231	Telatinib	<1 mg/mL	82 mg/mL	1 mg/mL
S3012	Pazopanib	<1 mg/mL	87 mg/mL	<1 mg/mL
S2769	Dovitinib (TKI-258) Dilactic Acid	70 mg/mL	90 mg/mL	<1 mg/mL
S8024	Tyrphostin AG 1296	<1 mg/mL	6 mg/mL	<1 mg/mL
S7765	Dovitinib (TKI258) Lactate	66 mg/mL	100 mg/mL	1 mg/mL
S7782	Dasatinib Monohydrate	<1 mg/mL	21 mg/mL	<1 mg/mL
S7781	Sunitinib	<1 mg/mL	25 mg/mL	<1 mg/mL
S8573	Sitravatinib (MGCD516)	<1 mg/mL	100 mg/mL	100 mg/mL
S8553	Avapritinib (BLU-285)	<1 mg/mL	66 mg/mL	3 mg/mL
S7003	AZD2932	<1 mg/mL	89 mg/mL	5 mg/mL
S7818	Pexidartinib (PLX3397)	<1 mg/mL	83 mg/mL	<1 mg/mL

c-Kit抑制剂（26）
新c-Kit产品

产品目录	产品描述	文献引用	实验数据
S1021	Dasatinib Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。	Nature, 2017, 543(7647):728-732 Cancer Discov, 2016, 6(7):727-39 Cancer Discov, 2011, 1(7):608-25	Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.
S1026	Imatinib Mesylate (STI571) Imatinib Mesylate (STI571)是一种口服生物有效的Imatinib甲磺酸盐，是一种多靶点抑制剂，作用于v-Abl，c-Kit和PDGFR，在无细胞和细胞试验中，IC50分别为0.6 μM，0.1 μM 和0.1 μM。	Cell Stem Cell, 2012, 10(2):210-7 Cancer Cell, 2014, 26(6):840-50 Sci Transl Med, 2014, 6(261):261ra152	THOC5 phospho-Y225 levels were assessed in the populations shown by flow cytometry following 24 h treatment with 5 μM imatinib, 150 nM dasatinib or 5 μM nilotinib. Results are displayed as mean fluorescence intensity (n= 4) ±s.e.m.
S1042	Sunitinib Malate Sunitinib Malate是一种多靶点RTK抑制剂，作用于VEGFR2 (Flk-1)和 PDGFRβ，在无细胞试验中IC50分别为80 nM 和2 nM，也会抑制c-Kit的活性。	Nature, 2011, 478(7369):349-55 Sci Transl Med, 2015, 7(284):284ra57 Cell Res, 2011, 21(7):1080-7	PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.
S1005	Axitinib Axitinib是一种多靶点抑制剂，作用于 VEGFR1，VEGFR2，VEGFR3，PDGFRβ和c-Kit，在猪主动脉内皮细胞中IC50分别为0.1 nM，0.2 nM，0.1-0.3 nM，1.6 nM和1.7 nM。	Cell, 2018, 173(1):117-129 Cancer Discov, 2012, 2(4):344-55 Clin Cancer Res, 2016, 22(8):1940-50	Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.
S1035	Pazopanib HCl (GW786034 HCl) Pazopanib HCl (GW786034 HCl)是一种新型多靶点抑制剂，作用于VEGFR1，VEGFR2，VEGFR3，PDGFR，FGFR，c-Kit和c-fms，在无细胞试验中IC50分别是10 nM，30 nM，47 nM，84 nM，74 nM，140 nM和146 nM。	Cancer Discov, 2013, 3(6):636-47 J Virol, 2011, 85(5):2296-303 J Cell Physiol, 2016, 231(10):2286-302	IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.
S8757^New	Ripretinib (DCC-2618) DCC-2618是一种具有口服活性的KIT和PDGFR-alpha抑制剂，对WT KIT、V654A KIT、T670I KIT、D816H KIT和D816V KIT的IC50分别为4 nM、8 nM、18 nM、5 nM和14 nM。
S8721^New	PDGFR inhibitor 1 PDGFR inhibitor 1是一种具有口服活性的KIT和PDGFR抑制剂，具有潜在的抗肿瘤活性。它还能抑制好几种其他激酶，包括VEGFR2、TIE2、PDGFR-beta和CSF1R，因此进而抑制肿瘤细胞的生长。
S5077^New	Regorafenib Monohydrate Regorafenib 瑞戈非尼是一种新型口服的多重激酶抑制剂，对VEGFR1、小鼠VEGFR2、小鼠VEGFR3、PDGFR-β、KIT、RET、RAF-1、B-RAF和B-RAF(V600E)的IC50分别为13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM。
S1018	Dovitinib (TKI-258, CHIR-258) Dovitinib (TKI-258, CHIR-258)是一种多靶点的RTK抑制剂，在无细胞试验中对III型(FLT3/c-Kit)作用最强，IC50为1 nM/2 nM，同时也作用于IV类(FGFR1/3)和V类(VEGFR1-4) RTKs，IC50为8-13 nM，但对InsR，EGFR，c-Met，EphA2，Tie2，IGF-1R和HER2作用较弱。Phase 4。	Cancer Res, 2013, 73(16):5195-205 Haematologica, 2011, 96(6):922-6 BRIT J CANCER, 2011, 104(1):75-82	In vitro assays on CUX1-FGFR1-expressing Ba/F3 cells. a. IL-3 deprivation of Ba/F3 cells transduced with CUX1-FGFR1 resulted in transformation to growth factor independent growth. The mean growth ±SEM of three separate measurements over four consecutive days is presented. b. The dose-response curves of CUX1-FGFR1-transduced Ba/F3 cells, treated with TKI258 and PKC412 for 48 hours in the absence or presence of IL-3 (2 ng/ml) are presented. Points represent the average results of two experiments done in triplicate plotted with the curve-fitting GraphPad Prism 5 software; bars, SD. The calculated IC50 for each inhibitor is indicated. c. Western blot analyses of CUX1-FGFR1-transformed Ba/F3 cells after treatment with PKC412 and TKI258. Phosphorylation of CUX1-FGFR1 and its downstream effectors STAT5 and RPS6K decreased with increasing inhibitor concentrations. Expression of total CUX1-FGFR1, STAT5 and RPS6K remained unaffected. d. Effect of PKC412 and TKI258 on apoptosis of CUX1-FGFR1-expressing Ba/F3 cells after treatment for 48 hours. The percentage of apoptotic plus necrotic CUX1-FGFR1-transduced Ba/F3 cells is indicated.
S1064	Masitinib (AB1010) Masitinib (AB1010)是一种新型的Kit和PDGFRα/β抑制剂，IC50分别为200 nM和540 nM/800 nM，但对ABL和c-Fms抑制作用较弱。Phase 3。	Hepatology, 2016, 64(2):488-500 Biomaterials, 2013, 34(38):9737-46 Mol Syst Biol, 2015, 11(1):789	H&E stained histology slides of A), C), and E) control implants and B), D), and F) drug-loaded implants for 14, 21 and 28 day time points respectively. Location of the implants is denoted by the asterisk ‘*’. Scale bar: 200 μm.
S1207	Tivozanib (AV-951) Tivozanib (AV-951)是一种有效的，选择性VEGFR抑制剂，作用于VEGFR1/2/3时，IC50分别为0.21 nM/0.16 nM/0.24 nM，也抑制PDGFR和c-Kit，作用于FGFR-1， Flt3， c-Met EGFR和IGF-1R活性较弱。Phase 3。	J Med Chem, 2015, Cell Physiol Biochem, 2013, 32(5):1541-50 J Chem Inf Model, 2014, 54(3):881-93	After serum-starvation for 24 h, the MCF7 cells were co-treated with 10 nM TPA and the indicated doses VEGFR inhibitor, Tivozanib, for 24 h. The levels of fibronectin, p-PKC-α, p-ERK, p-AKT, t-AKT and β-actin protein expression were analyzed by western blotting. The levels of fibronectin mRNA were analyzed by real-time PCR. The results are representative of three independent experiments. The values shown are the means ±SEM. * P < 0.05, ** P < 0.01 vs. control. # P < 0.05, ## P < 0.01 vs. TPA-treated cells. Con: control. LY: LY294002, U: UO126, Go: Go6983, Akt IV: Akt IV inhibitor.
S1032	Motesanib Diphosphate (AMG-706) Motesanib Diphosphate (AMG-706)是一种有效的ATP竞争性的VEGFR1/2/3抑制剂，IC50分别为2 nM/3 nM/6 nM；对Kit具有相似的抑制活性，对VEGFR选择性比PDGFR和Ret高10倍。Phase 3。	Cardiovasc Res, 2011, 91(3):402-11 Int J Cardiol, 2015, 183C:221-231 Mol Cell Endocrinol, 2013, 377(1-2):1-6	(C, D, E)^VEGFCM stimulated CXCR4 expression in CSC 24 h after ^VEGFCM treatment. CSC were untreated (Control, C), or treated with ^VEGFMSC-conditioned medium (^VEGFCM, D) or ^VEGFCM and VEGFR1 inhibitor AMG(E) followed by flow cytometry. AMG inhibited the expression of ^VEGFCM-induced CXCR4. (F) Quantitative analysis of CXCR4 expression by flow cytometry. CSC were treated with ^CtrlCM or ^VEGFCM with or without VEGFR specific inhibitors for VEGFR1 (AMG), VEGFR2 (VEGFR2-I), and VEGFR3 (MAZ).P , 0.05 vs. control, AMG, VEGFR2-I. and MAZ; #P , 0.05 vs. AMG and MAZ (n = 5). (G) ^CtrlCM promoted CSC migration. P , 0.05 vs. ^CtrlCM; OP , 0.01 vs. ^CtrlCM; &P , 0.05 vs. ^CtrlCM+AMG and <sup>Ctrl</sup>CM+MAZ (n ?15); @P , 0.01 vs. ^CtrlCM; PP , 0.01 vs. ^CtrlCM; $P , 0.05 vs. ^CtrlCM+AMG and ^CtrlCM+MAZ. Note: ^CtrlCM= ^CtrlMSC< mesenchymal stem cells>-conditioned medium
S1244	Amuvatinib (MP-470) Amuvatinib (MP-470)是一种有效的，作用于c-Kit， PDGFα和Flt3的多靶点抑制剂，IC50分别为10 nM， 40 nM和81 nM。Phase 2。	Nat Genet, 2012, 44(8):852-60 Cancer Res, 2014, 74(20):5878-90 Oncogene, 2014, 33(10):1316-24	Effects of treatment for 48h with a vehicle or the indicated doses of MP-470 in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments.
S1220	OSI-930 OSI-930是一种有效的Kit， KDR和CSF-1R抑制剂，IC50分别为80 nM， 9 nM和15 nM，对Flt-1， c-Raf和Lck具有适度的抑制活性，对PDGFRα/β， Flt-3和Abl抑制活性较弱。Phase 1。	Mol Syst Biol, 2015, 11(1):789 Biochem Pharmacol, 2012, 84(6):766-74 Int J Oncol, 2015, 47(1):122-32	RE-luc2P-HEK293 cells were pretreated with 1uM OSI-930 (green), 20uM TBB (blue), 10uM CKI-7 (purple), or 10uM H-89 (orange) for 16 h and infected with Y. enterocolitica WA or Y. pestis Ind195 at MOI 1 and 20, respectively, for 1 h. Following stimulation with 10 ng/ml TNF-α at 5 h post-infection, luciferase activity was measured 24 h post-infection. Results were determined from two independent experiments performed in triplicate. A"*" denotes that the % NF-κβ inhibition using the inhibitors was significantly different (p<0.05) compared to the no drug control (black). The relative NF-κB inhibition by Yersinia infection was determined as a percentage of luciferase activity in bacteria-infected cells relative to luciferase activity in bacteria-free control cells.
S1363	Ki8751 Ki8751是一种有效的，选择性的VEGFR2抑制剂，IC50为0.9 nM，作用于VEGFR2比作用于c-Kit， PDGFRα和FGFR-2选择性高40倍以上，对EGFR， HGFR和InsR没有抑制活性。	Cancer Lett, 2017, 385:12-20 Mol Cell Proteomics, 2012, 11(9):745-57 Cellular Signalling, 2016, 19;28(6):652-662	Ki8751, a VEGFR2 inhibitor, significantly mitigated the proliferation-stimulating effect of dying U87 cells on HUVEC-Fluc (one-way ANOVA, LSD, n=3).
S2231	Telatinib Telatinib是一种有效的VEGFR2/3， c-Kit和PDGFRα抑制剂，IC50分别为6 nM/4 nM， 1 nM和15 nM。Phase 2。	Biochem Pharmacol, 2014, 89(1):52-61 Clin Cancer Res, 2018, 24(11):2678-2687
S3012	Pazopanib Pazopanib是一种新型多靶点的VEGFR1，VEGFR2，VEGFR3，PDGFR，FGFR，c-Kit 和 c-Fms抑制剂，无细胞试验中IC50分别为10 nM，30 nM，47 nM，84 nM，74 nM，140 nM 和 146 nM。	Cancer Discov, 2013, 3(6):636-47 Clin Cancer Res, 2014, 19(9):2368-80 Clin Cancer Res, 2015, 21(5):1172-82
S2769	Dovitinib (TKI-258) Dilactic Acid Dovitinib (TKI-258) Dilactic Acid 是一种多靶点的RTK抑制剂，作用于III型(FLT3/c-Kit)最有效，IC50为1 nM/2 nM，也有效作用于IV型(FGFR1/3)和V型(VEGFR1-4)RTKs，IC50为8-13 nM，对InsR， EGFR， c-Met， EphA2， Tie2， IGFR1和HER2作用效果稍弱。Phase 4。	Cancer Res, 2013, 73(16):5195-205 Cancer Lett, 2016, 380(1):163-173 Br J Cancer, 2011, 104(1):75-82	In vitro assays on CUX1-FGFR1-expressing Ba/F3 cells. a. IL-3 deprivation of Ba/F3 cells transduced with CUX1-FGFR1 resulted in transformation to growth factor independent growth. The mean growth ±SEM of three separate measurements over four consecutive days is presented. b. The dose-response curves of CUX1-FGFR1-transduced Ba/F3 cells, treated with TKI258 and PKC412 for 48 hours in the absence or presence of IL-3 (2 ng/ml) are presented. Points represent the average results of two experiments done in triplicate plotted with the curve-fitting GraphPad Prism 5 software; bars, SD. The calculated IC50 for each inhibitor is indicated. c. Western blot analyses of CUX1-FGFR1-transformed Ba/F3 cells after treatment with PKC412 and TKI258. Phosphorylation of CUX1-FGFR1 and its downstream effectors STAT5 and RPS6K decreased with increasing inhibitor concentrations. Expression of total CUX1-FGFR1, STAT5 and RPS6K remained unaffected. d. Effect of PKC412 and TKI258 on apoptosis of CUX1-FGFR1-expressing Ba/F3 cells after treatment for 48 hours. The percentage of apoptotic plus necrotic CUX1-FGFR1-transduced Ba/F3 cells is indicated.
S8024	Tyrphostin AG 1296 Tyrphostin AG 1296是一种PDGFR抑制剂，IC50为0.3-0.5 μM，对EGFR没有抑制活性。	Onco Targets Ther, 2014, 7:425-32	After inoculation with KAT4 cells, administration of compounds including MK-2206 (100 mg/kg), tyrphostin AG 1296 (100 mg/kg), or a combination of MK-2206 (100 mg/kg) and tyrphostin AG 1296 (100 mg/kg) was performed. The combination of MK-2206 and tyrphostin AG 1296 induced significant apoptosis of KAT4 tumor cells in vivo measured by the terminal deoxynucleotidyl transferase dUTP nick end labeling assay (green), and nuclei were stained with Hoechst (blue).
S7765	Dovitinib (TKI258) Lactate Dovitinib (TKI258) Lactate是Dovitinib的乳酸盐，Dovitinib是一种多靶点的PTK抑制剂，主要对第III类(FLT3/c-Kit)发挥作用，IC50为1 nM/2 nM，对第IV 类(FGFR1/3)和第V 类(VEGFR1-4) RTKs也有效，IC50为8-13 nM，对InsR，EGFR，c-Met，EphA2，Tie2，IGFR1 和HER2作用较差。Phase 4。	Genome Biol, 2014, 15(8):428 Amino Acids, 2016, 48(7):1591-9 Neoplasia, 2013, 15(8):975-88	(c) Percent survival for the AGS cancer cell line is shown with FGFR2 inhibitors of varying specificity. (d) The KatoIII diffuse gastric cancer cell line was treated with FGFR2 inhibitors of varying specificity. The Y-axis depicts percent survival versus the X-axis with log concentrations. In all panels, error bars represent standard error of the mean. The difference in percent cell survival between KatoIII and AGS cells was statistically significant (P <0.05) at the three highest concentrations of all drugs, except Brivanib which was only significant at the highest concentration.
S7782	Dasatinib Monohydrate Dasatinib Monohydrate 是一种新型有效的多靶点抑制剂，作用于靶点Abl，Src 和 c-Kit，IC50分别为 <1 nM，0.8 nM 和 79 nM。	Nature, 2016, 534(7607):341-6 Cancer Discov, 2011, 1(7):608-25 Cell Stem Cell, 2012, 10(2):210-7
S7781	Sunitinib Sunitinib 是一种多靶点 RTK 抑制剂，以VEGFR2(Flk-1)和PDGFRβ为靶点，IC50为80 nM 和 2 nM，对c-Kit也有抑制作用。	Nature, 2011, 478(7369):349-55 Sci Transl Med, 2015, 7(284):284ra57 Cell Res, 2011, 21(7):1080-7	PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.
S8573	Sitravatinib (MGCD516) Sitravatinib (MGCD516)是一种新型的、靶向多种参与调节S180肉瘤细胞生长的RTKs的小分子抑制剂，包括c-Kit, PDGFRβ, PDGFRα, c-Met和Axl。
S8553	Avapritinib (BLU-285) Avapritinib (BLU-285)是一种小分子激酶抑制剂，可有效抑制PDGFRα D842V突变体的活性、在细胞背景下抑制PDGFRα D842V自我磷酸化（IC50=30 nM）；同时也是KIT突变（KIT D816V）的抑制剂（IC50=0.5 nM）。
S7003	AZD2932 AZD2932 是一种有效的多靶点蛋白酪氨酸激酶抑制剂，对VEGFR-2，PDGFRβ，Flt-3，和 c-Kit 的 IC50 分别为 8 nM，4 nM，7 nM，和 9 nM。
S7818	Pexidartinib (PLX3397) Pexidartinib (PLX3397)是一种口服有效的多靶点CSF-1R，Kit，和 Flt3受体酪氨酸激酶抑制剂，其IC50分别为20 nM, 10 nM 和 160 nM。Phase 3。	Nature, 2017, 541(7638):481-487 Nat Commun, 2017, 8:14293 FASEB J, 2018, 32(6):3336-3345	(a) Reduced tumour burden in PLX3397 (PLX) treated mice relative to untreated (NT) (n=6, P=.015; unpaired t-test). Bars represent total tumour volume with number of identified tumours indicated above each bar.

研究领域

产品类型

c-Kit

信号通路图

研究领域